Four-Year-Old Hospitalized in Serious Condition With Meningococcal Bacteria

A four-year-old boy from Holon has been hospitalized in serious condition at Wolfson Medical Center due to a severe invasive meningococcal infection. The child arrived at the pediatric emergency room with rapidly developing symptoms and was diagnosed with the invasive bacterial infection. His condition is currently stable.

Dr. Diana Tcher, head of pediatrics at Wolfson, described the meningococcus bacteria as causing one of the most aggressive and rapidly progressing infections in pediatric medicine. She explained that the bacteria can infect a healthy individual and lead to system collapse, septic shock, and life-threatening conditions within hours. The initial symptoms, such as fever, weakness, muscle aches, or headaches, are often non-specific and mimic common viral illnesses, but the disease can escalate dramatically within 24 to 48 hours, making prompt diagnosis and treatment critical.

The infection most commonly affects infants up to two years old, as well as individuals in crowded living conditions and those with compromised immune systems. Dr. Tcher urged parents and medical staff to be vigilant for warning signs, including a stiff neck, apathy, or a petechial rash (red-purple spots that do not disappear when pressed), and to seek immediate emergency medical attention if these are observed.

This case follows two infant deaths from meningococcal bacteria in June at Ichilov and Soroka hospitals. The incidents have reignited debate over the Bexsero vaccine, which protects against meningococcal B strain but is not part of the routine infant vaccination schedule. While recommended by the Ministry of Health and the Israel Pediatric Association for children up to age two, it is only available through supplementary insurance at a significant cost. The vaccine has been submitted to the Health Basket Committee for inclusion in the 2026 national health plan for the seventh time but has not been approved, with committee members citing its limited impact relative to its high cost and the fact that it only covers strain B among many others. According to Ministry of Health data from 2025, there were 56 recorded cases of meningococcal disease across all ages, with only eight from strain B, and two fatalities from other strains. The inclusion of a three-dose vaccine would also require extensive logistical planning for public health clinics.